News, archive: February 2017
It is very difficult to sum up the results of 2016 for the Russian pharmaceutical retail industry in one word. Despite the very pessimistic beginning and rather moderate optimism of the spring-summer season, the rate at which the demand was recovering in physical terms during the last months of 2016 surprised every single analyst. The development of the market is also quite optimistic, so that if the general economic situation does not deteriorate, we will be able to say that the crisis as ended and the industry had entered the phase of quantitative growth.
In January 2017, Russia imported 29.8 bln RUB worth of ready-made drugs (free circulation prices) and 6.8 bln RUB worth of in-bulk drugs, which are 20% and 90% higher than those of the same period of 2016, respectively. We saw the dynamics of the in-bulk import as high 8 months ago.
In 2016, Russia imported 1.57 bln RUB worth of veterinary APIs (free circulation prices), which is more than 40% higher than that of 2015. However, this is not the maximum: in 2015, we saw a 160% increase. In physical terms, the import amounted to 837.7 tons, which is 52% higher than that of 2015.
In 2016, Russia imported 59.3 bln RUB worth of APIs (free circulation prices), which is in monetary terms only 3.3% higher than that of 2015, making it the lowest increase over the past 6 years. In physical terms, the API import has shown the biggest increase, with 24%.